Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacqueline Majors

Vascular Surgery Southaven, MS Medical Doctor

NPI 1255690871 CMS profile 7231935

7601 Southcrest Pkwy, Ste 102, Southaven, MS 38671

Open in the dashboard

General payments

$49,214

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacqueline Majors of Southaven, MS is reported in the CMS Open Payments database as having received $49,214 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,414 89
2024 General $14,406 58
2023 General $3,407 32
2022 General $3,927 29
2021 General $1,733 24
2020 General $2,234 31
2019 General $94 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacqueline Majors
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Jacqueline Majors were reported at $23,414. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Jacqueline Majors Vascular Surgery median Middle half National median
2019 $94 $796 $226–$2,363 $163
2020 $2,234 $348 $118–$1,110 $114
2021 $1,733 $471 $158–$1,421 $132
2022 $3,927 $725 $222–$2,183 $149
2023 $3,407 $836 $257–$2,440 $160
2024 $14,406 $909 $252–$2,619 $164
2025 $23,414 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $35,374 121 payments
  2. Endologix, Inc. $2,690 12 payments
  3. AngioDynamics, Inc. $2,475 10 payments
  4. W. L. Gore & Associates, Inc. $1,693 13 payments
  5. Silk Road Medical, Inc. $1,634 13 payments
  6. Medtronic Vascular, Inc. $1,474 23 payments
  7. Penumbra, Inc. $1,124 10 payments
  8. Asahi Intecc USA, Inc. $384 2 payments
  9. Terumo Medical Corporation $333 8 payments
  10. Inari Medical, Inc. $298 2 payments
  11. Other $1,735 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,560 3 payments
  2. Food and Beverage $15,951 224 payments
  3. Travel and Lodging $12,703 37 payments
Products named General payments · program years 2019–2025
  1. HawkOne $22,428 34 payments
  2. TurboHawk $4,098 28 payments
  3. IN.PACT Admiral $3,529 15 payments
  4. MO.MA ULTRA $2,443 11 payments
  5. ANGIOVAC $1,793 3 payments
  6. ENDURANT IIS $1,723 16 payments
  7. ENROUTE Transcarotid Stent $1,621 12 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,621 12 payments
  9. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,217 8 payments
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,217 8 payments
  11. Other $13,429 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

80

Median for Vascular Surgery: 122

Drug cost

$10,163

Median for Vascular Surgery: $14,135

Branded share of claims

70%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $9,412
Clopidogrel Clopidogrel Bisulfate Brand 43 $418
Cilostazol Generic 12 $266
Atorvastatin Calcium Generic 12 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$558,846

Of which drugs: $18,229

Medicare patients

213

Average age 75

Services billed

8,824

107 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 58%
Diabetes 49%
Chronic kidney disease 40%
Heart failure 38%
Atrial fibrillation 32%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 41 6,651 $509
Injection, fentanyl citrate, 0.1 mg J3010 Office 53 148 $104
Injection, midazolam hydrochloride, per 1 mg J2250 Office 53 270 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record